Literature DB >> 4044625

6-Thioguanine: high-dose 2-H infusions in goats.

T J Schouten, R A De Abreu, E D Schretlen, M B van Leeuwen, J M van Baal, G A de Vaan.   

Abstract

6-Thioguanine (6TG) is poorly absorbed after oral administration. Bolus injections of 6TG result in high peak concentrations with relatively short-lived plasma concentrations. In vitro studies have shown the importance of prolonged exposure to 6TG. Therefore we administered 6TG by infusion at a dose rate of 2 mg/h over 2 h. In three goats we determined the plasma concentration-time curves of 6TG and its riboside (6TGR). A steady state was reached for 6TG and was almost reached for 6TGR within the 2 h of infusion. In one experiment we obtained several samples of CSF and observed good penetration of 6TG and 6TGR into CSF. Urinary excretion of 6TG and 6TGR was also quantitated. The amount of drug and metabolite excreted later than 4 h after the end of the infusion was negligible. By infusing 6TG, the problems of both erratic absorption after oral administration and acute renal toxicity after bolus injection, can be averted. In our opinion prolonged infusions of 6TG may be of advantage in humans suffering from actively proliferating malignant diseases, and thus should be studied.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044625     DOI: 10.1007/BF00402722

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Clinical evaluation of thioguanosine.

Authors:  I H KRAKOFF; R R ELLISON; C T TAN
Journal:  Cancer Res       Date:  1961-09       Impact factor: 12.701

2.  Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.

Authors:  L B Mellett
Journal:  Cancer Treat Rep       Date:  1977-07

3.  Sensitive high-performance liquid chromatographic determination of 6-mercaptopurine, 6-thioguanine, 6-mercaptopurine riboside and 6-thioguanosine in biological fluids.

Authors:  J M van Baal; M B van Leeuwen; T J Schouten; R A de Abreu
Journal:  J Chromatogr       Date:  1984-12-12

4.  6-mercaptopurine: pharmacokinetics in animals and preliminary results in children.

Authors:  T J Schouten; R A De Abreu; C H De Bruyn; E Van der Kleijn; M J Oosterbaan; E D Schretlen; G A De Vaan
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

5.  Phase II trial of iv 6-thioguanine in advanced colorectal carcinoma.

Authors:  J C Britell; C G Moertel; L K Kvols; M J O'Connell; J Rubin; A J Schutt
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct

6.  Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man.

Authors:  K Lu; J A Benvenuto; G P Bodey; J A Gottlieb; M G Rosenblum; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity.

Authors:  L L Wotring; J L Roti Roti
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

8.  6-Mercaptopurine: total body autoradiograms and plasma concentration-time curves of 6MP and metabolites from marmoset monkeys.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; G A de Vaan; E van der Kleijn
Journal:  Pediatr Hematol Oncol       Date:  1986       Impact factor: 1.969

9.  The effects of inhibitors of DNA biosynthesis on the cytotoxicity of 6-thioguanine.

Authors:  S H Lee; A C Sartorelli
Journal:  Cancer Biochem Biophys       Date:  1981

10.  Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.

Authors:  J S Lilleyman; L Lennard; C A Rees; G Morgan; J L Maddocks
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.